<< Вернуться к списку статей журнала

Том 11 №4 2009 год - Нефрология и диализ

Активаторы рецепторов витамина D и сосудистая кальцификация (Обзор литературы)

Земченков А.Ю. Герасимчук Р.П.

Аннотация: В обзоре изложено современное представление о механизмах развития и патогенезе сосудистой кальцификации при хронической болезни почек. Представлена роль витамина D в процессах, связанных с сосудистой кальцификацией. Приведены данные о различии влияния на сосудистую кальцификацию разных активаторов рецепторов витамина D. Рассмотрены другие факторы, оказывающие влияние на сосудистую кальцификацию, а также известные плейотропные эффекты активаторов рецепторов витамина D.

Для цитирования: Земченков А.Ю., Герасимчук Р.П. Активаторы рецепторов витамина D и сосудистая кальцификация (Обзор литературы). Нефрология и диализ. 2009. 11(4):276-291. doi:

Весь текст

Ключевые слова: сосудистая кальцификация, минеральные и костные нарушения, хроническая болезнь почек, активаторы рецепторов витамина D, vascular calcification, mineral and bone disorders, chronic kidney disease, VDRA

Список литературы:

1. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D // Нефрология и диализ. 2004. № 6 (2). С. 116–127.
2. Волков М.М., Гордеева Л.А., Смирнов А.В. Кальциноз брюшной аорты у пациентов с хронической болезнью почек // Нефрология. 2009. № 13 (3). С. 39–41.
3. Перекокин Ю.Н., Шило В.Ю., Гендлин Г.Е. и соавт. Скорость пульсовой волны и податливость аорты у больных на программном гемодиализе: связь с факторами риска, кальцинозом сердца и показателями внутрисердечной гемодинамики // Нефрология и диализ. 2004. № 6 (1). С. 62–69.
4. Шило В.Ю. Гиперпаратиреоз и кальцимиметики // Нефрология и диализ. 2009. В печати.
5. Agarwal R., Acharya M., Tian J. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease // Kidney Int. 2005. V. 68. P. 2823–2828.
6. Al-Aly Z., Shao J.S., Lai C.F. et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha dependent signals in diabetic Ldlr. mice // Arterioscler Thromb Vasc Biol. 2007. V. 27. P. 2589–2596.
7. Alborzi P., Patel N.A., Peterson C. et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial // Hypertension. 2008. V. 52. P. 249–255.
8. Alem A.M., Sherrard D.J., Gillen D.L. et al. Increased risk of hip fracture among patients with end-stage renal disease // Kidney Int. 2000. V. 58. P. 396–399.
9. Andress D. Nonclassical aspects of differential vitamin D receptor activation // Drugs. 2007. V. 67. P. 1999–2012.
10. Arcidiacono M.V., Sato T., Alvarez-Hernandez D. et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease // J Am Soc Nephrol. 2008. V. 19. P. 310–20.
11. Asmus H.G., Braun J., Krause R. et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density // Nephrol Dial Transplant. 2005. V. 20. P. 1653–1661.
12. Beer T.M. Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic // Mol Cancer Ther. 2004. V. 3. P. 373–381.
13. Block G.A., Klassen P.S., Lazarus J.M. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis // J Am Soc Nephrol. 2004. V. 15. P. 2208–22218.
14. Block G.A., Martin K.J., de Francisco A.L.M. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis // N Engl J Med. 2004. V. 350. P. 1516–1525.
15. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management // Am J Kidney Dis. 2000. V. 35. P. 1226–1237.
16. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients // Kidney Int. 2007. V. 71. P. 438–441.
17. Bodyak N., Ayus J.C., Achinger S. et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals // Proc Natl Acad Sci USA. 2007. V. 104. P. 16810–16815.
18. Brewster U.C. Dermatological disease in patients with CKD // Am J Kidney Dis. 2008. V. 51. P. 331–344.
19. Brucculeri M., Cheigh J., Bauer G., Serum D. Long term intravenous sodium thiosulphate in the treatment of a patient with calciphylaxis // Semin Dial. 2005. V. 18. P. 431–434.
20. Byon C.H., Javed A., Dai Q. et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling // J Biol Chem 2008. V. 283. P. 15319–15327.
21. Cardus A., Panizo S., Parisi E. et al. Differential effects of vitamin D analogs on vascular calcification // J Bone Miner Res. 2007. V. 22. P. 860–866.
22. Cardus A., Parisi E., Gallego C. et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway // Kidney Int. 2006. V. 69. P. 1377–1384.
23. Chandra P., Binongo J.N., Ziegler T.R. et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study // Endocr Pract. 2008. V. 14. P. 10–17.
24. Chen N.X., Duan D., O’Neill K.D., Moe S.M. High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells // Nephrol Dial Transplant. 2006. V. 21. P. 3435–3442.
25. Chen N.X., Duan D., O’Neill K.D. et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells // Kidney Int. 2006. V. 70. P. 1046–1053.
26. Chen N.X., O’Neill K.D., Chen X. et al. Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins // Am J Physiol Renal Physiol. 2007. V. 292. F599–F606.
27. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients // Kidney Int. 2002. V. 62. P. 245–52.
28. Chertow G.M., Raggi P., Chasan-Taber S. et al. Determinants of progressive vascular calcification in haemodialysis patients // Nephrol Dial Transplant. 2004. V. 19. P. 1489–1496.
29. Civilibal M., Caliskan S., Adaletli I. et al. Coronary artery calcifi cations in children with end-stage renal disease // Pediatr Nephrol. 2006. V. 21. P. 1426–1433.
30. Coyne D., Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD // Am J Kidney Dis. 2006. V. 47. P. 263–276.
31. Cozzolino M., Fallabrino G., Pasho S. et al. Importance of Vitamin D Receptor Activation in Clinical Practice // Contrib Nephrol. 2009. V. 163. P. 213–218.
32. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperperathyroidism in a haemodialysis patient // Nephrol Dial Transplant Plus. 2008. V. 1. P. 148–150.
33. Cozzolino M., Galassi A., Gallieni M., Brancaccio D. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol // Curr Vasc Pharmacol. 2008. V. 6. P. 148–153.
34. Cozzolino M., Brandenburg V. Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the “U” // Clinical Nephrology. 2009. V. 71 (6). P. 593–601.
35. Cunningham J., Danese M., Olson K. et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism // Kidney Int. 2005. V. 68. P. 1793–800.
36. D’Haese P.C., Spasovski G.B., Sikole A. et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients // Kidney Int. Suppl. 2003. V. 85. S73–78.
37. Danese M.D., Belozeroff V., Smirnakis K., Rothman K.J. Consistent control of mineral and bone disorder in incident hemodialysis patients // Clin J Am Soc Nephrol 2008. V. 3. P. 1423–1429.
38. de Zeeuw D. Targeting proteinuria as a valid surrogate for individualized kidney protective therapy // Am J Kidney Dis. 2008. V. 51. P. 713–716.
39. Derici U., El Nahas A.M. Vascular calcifications in uremia: Old concepts and new insights // Semin Dial. 2006. V. 19. P. 60–68.
40. Di Iorio B.R., Minutolo R., De Nicola L. et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure // Kidney Int. 2003. V. 64. P. 1822–1828.
41. Elder G., Faull R., Branley P., Hawley C. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone // Nephrology (Carlton). 2006. V. 11 (Suppl 1). S230–261.
42. Fiedler R. Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis // Clin Drug Invest. 2007. V. 27 (12). P. 865–866.
43. Fishbane S., Chittineni H., Packman M. et al. Oral Paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial // Am J Kidney Dis. 2009. V. 54 (4). P. 647–652.
44. Fliser D., Kollerits B., Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study // J Am Soc Nephrol. 2007. V. 18. P. 2600–2608.
45. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease // Am J Kidney Dis. 1998. V. 32. S112–S119.
46. Franceschi R.T., Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways // J Cell Biochem. 2003. V. 88. P. 446–454.
47. Fukagawa M., Yumita S., Akizawa T. et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients // Nephrol Dial Transplant. 2008. V. 23. P. 328–335.
48. Gafor A.H.A., Saidi R., Yean L.C. et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism // Nephrology. 2009. V. 14, P. 488–492.
49. Ganesh S.K., Stack A.G., Levin N.W. et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients // J Am Soc Nephrol. 2001. V. 12. P. 2131–2138.
50. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., Yang H. Regulation of vascular calcification: Roles of phosphate and osteopontin // Circ Res. 2005. V. 96. P. 717–722.
51. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study // Arch Intern Med. 2008. V. 168. P. 1174–1180.
52. Goldsmith D.J., Covic A., Sambrook P.A., Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis // Nephron. 1997. V. 77. P. 37–43.
53. Guerin A.P., London G.M., Marchais S.J., Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease // Nephrol Dial Transplant. 2000. V. 15. P. 1014–1021.
54. Guerra G., Shah R.C., Ross E.A. Rapid resolution of calciphylaxis with intravenous sodium thiosulphate and continuous venovenous haemofiltration using low calcium replacement fluid // Nephrol Dial Transplant. 2005. V. 20. P. 1260–1262.
55. Gutierrez O., Isakova T., Andress D.L. et al. Racial differences in the prevalence and severity of disordered mineral metabolism in chronic kidney disease // ASN Annual Meeting. San Francisco, CA. 2007 Nov 2–5.
56. Gutierrez O.M., Mannstadt M., Isakova T. et al. fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // N Engl J Med. 2008. V. 359. P. 584–592.
57. Helming L., Bose J., Ehrchen J. et al. 1 Alpha 25-dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation // Blood. 2005. V. 106. P. 4351–4358.
58. Hirata M., Katsumata K., Endo K. et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3 // Nephrol Dial Transplant. 2003. V. 18. P. 1770–1776.
59. Jono S., McKee M.D., Murry C.E. et al. Phosphate regulation of vascular smooth muscle cell calcification // Circ Res. 2000. V. 87. E10–E17.
60. Joy M.S., Finn W.F. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia // Am J Kidney Dis. 2003. V. 42. P. 96–107.
61. Joy M.S., Karagiannis P.C., Peyerl F.W. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment // J Manag Care Pharm. 2007. V. 13. P. 397–411.
62. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of timevarying indicators of bone disease in maintenance hemodialysis patients // Kidney Int. 2006. V. 70. P. 771–780.
63. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease // Arch Intern Med. 2008. V. 168. P. 397–403.
64. Krajisnik T., Bjorklund P., Marsell R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells // J Endocrinol. 2007. V. 195. P. 125–131.
65. Kuhlmann A., Haas C.S., Gross M.L. et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat // Am J Physiol Renal Physiol. 2004. V. 286. F526–F533.
66. Kuro-o M. Klotho as a regulator of oxidative stress and senescence // Biol Chem. 2008. V. 389. P. 233–241.
67. Kyritsis I., Gombou A., Griveas I. et al. Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism // Int J Artif Organs. 2008. V. 31. P. 742–744.
68. Lazaro R.P., Kirshner H.S. Proximal muscle weakness in uremia. Case reports and review of the literature // Arch Neurol. 1980. V. 37. P. 555–558.
69. Lee J.S., Basalyga D.M., Simionescu A. et al. Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses // Am J Pathol. 2006. V. 168. P. 490–498.
70. Levin A., Gutierrez O., Andress D.L., Wolf M. Deficiencies of 25D, 1,25D and inflammation are associated with albuminuria // ASN Annual Meeting. San Francisco, CA. 2007 Nov 2–5.
71. Li X., Yang H.Y., Giachelli C.M. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification // Circ Res. 2006. V. 98. P. 905–912.
72. Li Y.C., Kong J., Wei M. et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system // J Clin Invest. 2002. V. 110. P. 229–238.
73. Liberman M., Bassi E., Martinatti M.K. et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification // Arterioscler Thromb Vasc Biol. 2008. V. 28. P. 463–470.
74. Liu P.T., Stenger S., Li H. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response // Science. 2006. V. 311. P. 1770–1773.
75. Liu S., Gupta A., Quarles L.D. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization // Curr Opin Nephrol Hypertens. 2007. V. 16. P. 329–335.
76. Lomashvili K., Garg P., O’Neill W.C. Chemical and hormonal determinants of vascular calcification in vitro // Kidney Int. 2006. V. 69. P. 1464–1470.
77. London G.M., Guerin A.P., Marchais S. et al. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality // Nephrol Dial Transplant. 2003. V. 18. P. 1731–1740.
78. Malluche H.H., Monier-Faugere M.C., Wang G. et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism // Clin. Nephrol. 2008. V. 69. P. 269–278.
79. Malluche H.H., Siami G.A., Swanepoel C. et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years // Clin Nephrol. 2008. V. 70. P. 284–295.
80. Mandayam S., Shahinian V.B. Are chronic dialysis patients at increased risk for cancer? // J Nephrol. 2008. V. 21. P. 166–174.
81. Mathew S., Lund R.J., Chaudhary L.R. et al. Vitamin D Receptor Activators Can Protect against Vascular Calcification // J Am Soc Nephrol. 2008. V. 19. P. 1509–1519.
82. Mehrotra R., Kermah D., Budoff M. et al. Hypovitaminosis D in chronic kidney disease // Clin J Am Soc Nephrol. 2008. V. 3. P. 1144–1151.
83. Meissner M., Gille J., Kayfmann R. Calciphylaxis: No therapeutic concepts for a poorly understood syndrome? // J Dtsch Dermatol Ges. 2006. V. 4. P. 1037–1044.
84. Melamed M.L., Muntner P., Michos E.D. et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004 // Arterioscler Thromb Vasc Biol. 2008. V. 28. P. 1179–1185.
85. Messa P., Macбrio F., Yaqoob M. et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism // Clin J Am Soc Nephrol. 2008. V. 3. P. 36–45.
86. Mitsopoulos E., Zanos S. Ginikopoulou E et al. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism // Am J Kidney Dis. 2006. V. 48. P. 114–121.
87. Mizobuchi M., Finch J.L., Martin D.R., Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats // Kidney Int. 2007. V. 72. P. 709–715.
88. Mizobuchi M., Finch J.L., Martin D.R., Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats // Kidney Int. 2007. V. 72. P. 709–715.
89. Moe S., Drueke T., Cunningham J. et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2006. V. 69. P. 1945–1953.
90. Mohammed I.A., Sekar V., Bubtana A.J. et al. Proximal calciphylaxis treated with calcimimetic cinacalcet // Nephrol Dial Transplant. 2008. V. 23. P. 387–389.
91. Mohler E.R. 3rd, Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves // Circulation. 2001. V. 103. P. 1522–1528.
92. Morony S., Tintut Y., Zhang Z. et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(/) mice // Circulation. 2008. V. 117. P. 411–420.
93. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease // Am J Kidney Dis. 2003. V. 42. S1–201.
94. Ogata H., Koiwa F., Ito H., Kinugasa E. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients // Ther Apher Dial. 2006. V. 10. P. 355–363.
95. Ogata H., Koiwa F., Kinugasa E., Akizawa T. CKD-MBD: Impact on management of kidney disease // Clin Exp Nephrol. 2007. V. 11. P. 261–268.
96. Olgaard K., Lewin E. Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease // Nephrol Dial Transplant. 2008. V. 23. P. 1786–1789.
97. Palmer S.C., McGregor D.O., Macaskill P. et al. Meta-analysis: Vitamin D compounds in chronic kidney disease // Ann Intern Med. 2007. V. 147. P. 840–853.
98. Pasch A. Bone mass gain after parathyroidectomy // Kidney Int. 2008. V. 74. P. 697–699.
99. Patel T.V., Singh A.K. Role of Vitamin D in Chronic Kidney Disease // Semin Nephrol. 2009. V. 29 (2). P. 113–121.
100. Pei Y.P., Greenwood C.M., Chery A.L., Wu G.G. Racial differences in survival of patients on dialysis // Kidney Int. 2000. V. 58. P. 1293–1299.
101. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation // J Immunol. 2000. V. 164. P. 2405–2411.
102. Perez-Castrillon J.L., Vega G., Abad L. et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease // Am J Cardiol. 2007. V. 99. P. 903–905.
103. Pilz S., Marz W., Wellnitz B. et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography // J Clin Endocrinol Metab. 2008. V. 93. P. 3927–3935.
104. Qin X., Corriere M.A., Matrisian L.M., Guzman R.J. Matrix metalloproteinase inhibition attenuates aortic calcification // Arterioscler Thromb Vasc Biol. 2006. V. 26. P. 1510–1516.
105. Qunibi W.Y., Hootkins R.E., McDowell L.L. et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) // Kidney Int. 2004. V. 65. P. 1914–1926.
106. Raymond C.B., Wazny L.D. Sodium thiosulphate, biphosphonates and cinacalcet for treatment of calciphylaxis // Am J Health Syst Pharm. 2008. V. 65. P. 1419–1429.
107. Redman R., Misita C.P., Stafford D.W. et al. Warfarin-associated calciphylaxis in a patient without renal failure or hyperparathyroidism: Investigation of matrix GLA protein // Blood. 2005. V. 106. 3969A.
108. Reynolds J.L., Joannides A.J., Skepper J.N. et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD // J Am Soc Nephrol. 2004. V. 15. P. 2857–2867.
109. Reynolds J.L., Skepper J.N., McNair R. et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification // J Am Soc Nephrol. 2005. V. 16. P. 2920–2930.
110. Rogers N.M., Teubner D.J.O., Coates T.H. Calcific uremic arteriolopathy: Advances in pathogenesis and treatment // Semin Dial. 2007. V. 20. P. 150–157.
111. Rosery H., Bergemann R., Marx S.E. et al. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis // Clin Drug Invest. 2006. V. 26. P. 629–638.
112. Ross E.A., Tian J., Abboud H. et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis // Am J Nephrol. 2008. V. 28. P. 97–106.
113. Scatena M., Liaw L., Giachelli C.M. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease // Arterioscler Thromb Vasc Biol. 2007. V. 27. P. 2302–2309.
114. Scatena M., Liaw L., Giachelli C.M. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease // Arterioscler Thromb Vasc Biol. 2007. V. 27. P. 2302–2309.
115. Schleithoff S.S., Zittermann A., Tenderich G. et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial // Am J Clin Nutr. 2006. V. 83. P. 754–759.
116. Schoppet M., Al-Fakhri N., Franke F.E. et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis // J Clin Endocrinol Metab. 2004. V. 89. P. 4104–4112.
117. Schurgers L.J., Teunissen K.J., Knapen M.H. et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification // Arterioscler Thromb Vasc Biol. 2005. V. 25. P. 1629–1633.
118. Shinaberger C.S., Kopple J.D., Kovesdy C.P. et al. Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients // Clin J Am Soc Nephrol. 2008. V. 3. P. 1769–1776.
119. Shioi A., Katagi M., Okuno Y. et al. Induction of bonetype alkaline phosphatase in human vascular smooth muscle cells: Roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages // Circ Res. 2002. V. 91. P. 9–16.
120. Shoben A.B., Rudser K.D., de Boer I.H. et al. Association of oral calcitriol with improved survival in nondialyzed CKD // J Am Soc Nephrol. 2008. V. 19. P. 1613–1619.
121. Shoji T., Shinohara K., Kimoto E. et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population // Nephrol Dial Transplant. 2004. V. 19. P. 179–184.
122. Shroff R.C., Shanahan C.M. The vascular biology of calcification // Semin Dial. 2007. V. 20. P. 103–109.
123. Slatopolsky E., Finch J.L., Brown A.J. et al. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxybishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism // J Bone Miner Res. 2007. V. 22. P. 686–694.
124. Somjen D., Weisman Y., Kohen F. et al. 25-hydroxyvitamin D3–1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds // Circulation. 2005. V. 111. P. 1666–1671.
125. Sprague S.M., Llach F., Amdahl M. et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism // Kidney Int. 2003. V. 63. P. 1483–1490.
126. Szeto C.C., Chow K.M., Kwan B.C. et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: An uncontrolled trial // Am J Kidney Dis. 2008. V. 51. P. 724–731.
127. Teng M., Wolf M., Lowrie E. et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy // N Engl J Med. 2003. V. 349. P. 446–456.
128. Teng M., Wolf M., Ofsthun M.N. et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study // J Am Soc Nephrol. 2005. V. 16. P. 1115–1125.
129. Tentori F., Hunt W.C., Stidley C.A. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs // Kidney Int. 2006. V. 70. P. 1858–1865.
130. Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter // Kidney Int. 2008. V. 74. P. 141–143.
131. Tokmak F., Quack I., Schieren G. et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients // Nephrol Dial Transplant. 2008. V. 23. P. 4016–4020.
132. Tonelli M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease // Circulation. 2005. V. 112. P. 2627–2633.
133. Tonelli M. Vitamin D in patients with chronic kidney disease: Nothing new under the sun // Ann Intern Med. 2007. V. 147. P. 880–881.
134. Toussaint N., Cooney P., Kerr P.G. Review of dialysate calcium concentration in hemodialysis // Hemodial Int. 2006. V. 10. P. 326–337.
135. Towler D.A. Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype // Arterioscler Thromb Vasc Biol. 2005. V. 25. P. 651–654.
136. Towler D.A. Vascular biology and bone formation: Hints from HIF // J Clin Invest. 2007. V. 117. P. 1477–1480.
137. Tyson K.L., Reynolds J.L., McNair R. et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification // Arterioscler Thromb Vasc Biol. 2003. V. 23. P. 489–494.
138. Tzanakis I.P., Papadaki A.N., Wei M. et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial // Int Urol Nephrol. 2008. V. 40. P. 193–201.
139. Valle C., Rodriguez M., Santamarнa R. et al. Cinacalcet reduces the set point of the PTH-calcium curve // J Am Soc Nephrol. 2008. V. 19. P. 2430–2436.
140. Van Eps C.L., Jeffries J.K., Anderson J.A. et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis // Nephrology (Carlton). 2007. V. 12. P. 224–233.
141. Vanholder R., Van Biesen W. Incidence of infectious morbidity and mortality in dialysis patients // Blood Purif. 2002. V. 20. P. 477–480.
142. Vargemezis V., Liakopoulos V., Kriki P. et al. Pivotal Role of Paricalcitol in the Treatment of Calcific Uremic Arteriolopathy in the Presence of a Parathyroid Adenoma // Am J Kidney Dis. 2009. May 27. [Epub ahead of print].
143. Velasco N., MacGrecor M.S., Innes A., MacKay I. Successful treatment of calciphylaxis with cinacalcet- an alternative to parathyroidectomy? // Nephrol Dial Transplant. 2000. V. 21. P. 1999–2004.
144. Wang H.Y., Yu C.C., Huang C.C. Successful treatment of severe calciphylaxis in a hemodialysis patient using low-calcium dialysate and medical parathyroidectomy: Case report and literature review // Ren Fail. 2004. V. 26. P. 77–82.
145. Wang T.J., Pencina M.J., Booth S.L. et al. Vitamin D deficiency and risk of cardiovascular disease // Circulation. 2008. V. 117. P. 503–511.
146. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., Demer L.L. Active serum vitamin D levels are inversely correlated with coronary calcification // Circulation. 1997. V. 96. P. 1755–1760.
147. Wills M.R., Savory J. Aluminium poisoning: Dialysis encephalopathy, osteomalacia, and anaemia // Lancet. 1983. V. 2. P. 29–34.
148. Wolf G., Chen S., Han D.C., Ziyadeh F.N. Leptin and renal disease // Am J Kidney Dis. 2002. V. 39. P. 1–11.
149. Wolisi G.O., Moe S.M. The role of vitamin D in vascular calcification in chronic kidney disease // Semin Dial. 2005. V. 18. P. 307–314.
150. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells // Atherosclerosis. 2006. V. 186. P. 20–28.
151. Xiang W., Kong J., Chen S. et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems // Am J Physiol Endocrinol Metab. 2005. V. 288. E125–132.
152. Yajima A., Inaba M., Tominaga Y., Ito A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy // Kidney Int. 2008. V. 74. P. 775–781.
153. Young E.W., Albert J.M., Satayathum S. et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study // Kidney Int. 2005. V. 67. P. 1179–1187.
154. Zhou C., Lu F., Cao K. et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice // Kidney Int. 2008. V. 74. P. 170–179.
155. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease // Prog Biophys Mol Biol. 2006. V. 92. P. 39–48.

Другие статьи по теме

• Две стороны одной медали: роль недостаточного и избыточного веса в патогенезе хронической болезни почек
• Гиперпаратиреоз и минеральная плотность кости у больных с хронической болезнью почек: влияние паратиреоидэктомии
• Особенности проведения заместительной почечной терапии у больного гемофилией А
• Рецептор витамина D: новая терапевтическая мишень при заболевании почек